Id |
Subject |
Object |
Predicate |
Lexical cue |
T376 |
0-175 |
Sentence |
denotes |
More recently, Li et al. found no statistically significant clinical improvement or mortality reduction in a randomized clinical trial with CP-treated COVID-19 patients (274). |
T377 |
176-345 |
Sentence |
denotes |
However, the authors reported that CP treatment is potentially beneficial to critically ill patients by suggesting a possible antiviral efficiency of high titer of nAbs. |
T378 |
346-657 |
Sentence |
denotes |
Notably, there are clinical controversies, ethical issues, and potential risks associated with convalescent plasma therapy (275), such as the possibility of ADE development, exacerbating the disease severity, and causing a significant illness in future exposure to coronaviruses infection (268, 276, 277) (REF). |
T379 |
658-945 |
Sentence |
denotes |
Divergences between studies may be caused by variations in the composition of CP, which is highly variable and includes a variety of blood-derived components, timing of CP administration, titer of the specific antibody in administered plasma, and presence of blood borne pathogens (268). |
T380 |
946-1067 |
Sentence |
denotes |
Nonetheless, understanding the efficacy and safety of CP therapy relies on the completion of the ongoing clinical trials. |